FI115911B - Fuusioidut pyrrolokarbatsolit, menetelmä niiden valmistamiseksi ja niiden käyttö - Google Patents

Fuusioidut pyrrolokarbatsolit, menetelmä niiden valmistamiseksi ja niiden käyttö Download PDF

Info

Publication number
FI115911B
FI115911B FI971479A FI971479A FI115911B FI 115911 B FI115911 B FI 115911B FI 971479 A FI971479 A FI 971479A FI 971479 A FI971479 A FI 971479A FI 115911 B FI115911 B FI 115911B
Authority
FI
Finland
Prior art keywords
pyrrolo
alkyl
compound
med
eller
Prior art date
Application number
FI971479A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971479A (fi
FI971479A0 (fi
Inventor
Robert L Hudkins
Ernest Knight Jr
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27502273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI115911(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/323,755 external-priority patent/US5475110A/en
Priority claimed from US08/427,160 external-priority patent/US5591855A/en
Priority claimed from US08/452,335 external-priority patent/US5594009A/en
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of FI971479A0 publication Critical patent/FI971479A0/fi
Publication of FI971479A publication Critical patent/FI971479A/fi
Application granted granted Critical
Publication of FI115911B publication Critical patent/FI115911B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI971479A 1994-10-14 1997-04-09 Fuusioidut pyrrolokarbatsolit, menetelmä niiden valmistamiseksi ja niiden käyttö FI115911B (fi)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US32375594 1994-10-14
US08/323,755 US5475110A (en) 1994-10-14 1994-10-14 Fused Pyrrolocarbazoles
US08/427,160 US5591855A (en) 1994-10-14 1995-04-24 Fused pyrrolocarbazoles
US42716095 1995-04-24
US08/452,335 US5594009A (en) 1994-10-14 1995-05-26 Fused pyrrolocarbazoles
US45233595 1995-05-26
US52679895 1995-09-11
US08/526,798 US5705511A (en) 1994-10-14 1995-09-11 Fused pyrrolocarbazoles
PCT/US1995/012761 WO1996011933A1 (en) 1994-10-14 1995-10-03 Fused pyrrolocarbazoles
US9512761 1995-10-03

Publications (3)

Publication Number Publication Date
FI971479A0 FI971479A0 (fi) 1997-04-09
FI971479A FI971479A (fi) 1997-06-11
FI115911B true FI115911B (fi) 2005-08-15

Family

ID=27502273

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971479A FI115911B (fi) 1994-10-14 1997-04-09 Fuusioidut pyrrolokarbatsolit, menetelmä niiden valmistamiseksi ja niiden käyttö

Country Status (17)

Country Link
US (1) US5705511A (pt)
EP (2) EP0785938B1 (pt)
JP (1) JP2001509775A (pt)
AT (2) ATE211472T1 (pt)
AU (1) AU705306B2 (pt)
BR (1) BR9509348A (pt)
CA (1) CA2202487C (pt)
DE (2) DE69524882T2 (pt)
DK (2) DK1088823T3 (pt)
ES (2) ES2235769T3 (pt)
FI (1) FI115911B (pt)
HK (1) HK1036622A1 (pt)
MX (1) MX9702682A (pt)
NO (1) NO308996B1 (pt)
NZ (1) NZ296244A (pt)
PT (2) PT785938E (pt)
WO (1) WO1996011933A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
JP2001515032A (ja) * 1997-08-15 2001-09-18 セフアロン・インコーポレーテツド 前立腺がんを治療するためのチロシンキナーゼ阻害剤と化学的去勢術の組み合わせ法
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
DE69911935T3 (de) * 1998-03-13 2008-02-07 The University Of British Columbia, Vancouver Granulatimide-derivate zur behandlung von krebs
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
BR9913190A (pt) * 1998-08-26 2001-12-11 Cephalon Inc Modulação de proteìnas quinase de linhagemmúltipla
AU763435B2 (en) * 1998-09-25 2003-07-24 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
IL154311A0 (en) * 2000-08-11 2003-09-17 Cephalon Inc Modulating multiple lineage kinase proteins
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
AU2001285205B2 (en) * 2000-08-25 2007-03-01 Cephalon, Inc. Fused pyrrolocarbazoles against inflammation
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
RU2003131269A (ru) 2001-03-22 2005-05-10 Бристол-Маерс Сквибб Компани (Us) Производные индолопирролокарбазолов и сахаров, цитотоксические и селективные по отношению к топоизомеразе i
AR035971A1 (es) * 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
US7482134B2 (en) * 2002-06-05 2009-01-27 Seoul National University Industry Foundation Signals and molecular species involved in senescence
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
FR2845997B1 (fr) * 2002-10-18 2004-12-24 Servier Lab Nouveaux derives de[1,4]benzodioxino[2,3-e]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
WO2005014003A1 (en) * 2003-07-23 2005-02-17 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
KR100734429B1 (ko) * 2004-12-06 2007-07-03 재단법인서울대학교산학협력재단 노화에 관여하는 신호 및 분자종
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
WO2007002670A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Method of lowering intraocular pressure
US20080199850A1 (en) 2005-10-11 2008-08-21 Merck Patent Gmbh Egfr Dependent Modulation of Chemokine Expression and Influence on Therapy and Diagnosis of Tumors and Side Effects Thereof
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
KR100831367B1 (ko) 2007-02-16 2008-05-22 재단법인서울대학교산학협력재단 아데닐일 시클라아제의 억제제를 노화 세포에 처리하는 단계를 포함하는 세포의 노화 조절방법 및 아데닐일 시클라아제의 억제제를 포함하는 세포 노화 조절용 조성물
CN101861159A (zh) * 2007-10-19 2010-10-13 马尔药品公司 改进的抗肿瘤治疗
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
CA2932121A1 (en) * 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
EP2367829B1 (en) * 2008-11-19 2013-01-02 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2192121A1 (en) 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
CN102482279B (zh) 2009-03-30 2015-08-12 德山新勒克斯 有机电子装置及其化合物与终端机
KR101182438B1 (ko) * 2009-08-14 2012-09-12 삼성디스플레이 주식회사 유기 발광 소자
US20150320861A1 (en) 2012-12-21 2015-11-12 Sykehuset Sørlandet Hf Egfr targeted therapy of neurological disorders and pain
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
DE102017117328A1 (de) * 2017-07-31 2019-01-31 Mitsubishi Polyester Film Gmbh Peelfähige Polyesterfolie, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552842A (en) * 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5185260A (en) * 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US6271242B1 (en) * 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
DE4337521A1 (de) * 1993-11-03 1995-05-04 Teves Gmbh Alfred Verfahren zur Funktionsprüfung eines hydraulischen Aggregats

Also Published As

Publication number Publication date
ATE286055T1 (de) 2005-01-15
ATE211472T1 (de) 2002-01-15
FI971479A (fi) 1997-06-11
NO971677D0 (no) 1997-04-11
ES2235769T3 (es) 2005-07-16
FI971479A0 (fi) 1997-04-09
US5705511A (en) 1998-01-06
DK1088823T3 (da) 2005-04-25
DE69524882D1 (de) 2002-02-07
CA2202487A1 (en) 1996-04-25
EP0785938A1 (en) 1997-07-30
CA2202487C (en) 2008-06-17
NZ296244A (en) 1998-11-25
HK1036622A1 (en) 2002-01-11
EP0785938B1 (en) 2002-01-02
AU3998695A (en) 1996-05-06
WO1996011933A1 (en) 1996-04-25
JP2001509775A (ja) 2001-07-24
DE69533899D1 (de) 2005-02-03
DE69524882T2 (de) 2002-09-12
ES2170812T3 (es) 2002-08-16
DK0785938T3 (da) 2002-04-22
DE69533899T2 (de) 2005-12-08
EP1088823A1 (en) 2001-04-04
BR9509348A (pt) 1997-11-04
PT1088823E (pt) 2005-03-31
NO971677L (no) 1997-06-11
EP1088823B1 (en) 2004-12-29
PT785938E (pt) 2002-06-28
MX9702682A (es) 1998-02-28
NO308996B1 (no) 2000-11-27
AU705306B2 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
FI115911B (fi) Fuusioidut pyrrolokarbatsolit, menetelmä niiden valmistamiseksi ja niiden käyttö
US5591855A (en) Fused pyrrolocarbazoles
US5475110A (en) Fused Pyrrolocarbazoles
US5594009A (en) Fused pyrrolocarbazoles
JP4776842B2 (ja) 異性体の縮合ピロロカルバゾール類およびイソインドロン類
US6610684B2 (en) Fused azepinone cyclin dependent kinase inhibitors
JP2021530442A (ja) 縮合三環系複素環化合物およびその治療上の使用
PL198434B1 (pl) Nowe mostkowane indenopirolokarbazole, kompozycje farmaceutyczne zawierające te związki i ich zastosowanie
AU4376897A (en) Novel indole-2,3-dione-3-oxime derivatives
JP3170584B2 (ja) 新規なイサチンオキシム誘導体類、その製造および使用
EP1756112A1 (en) Pyrrolobenzimidazolones and their use as antiproliferative agents
WO2003057161A2 (en) BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF
KR100460783B1 (ko) 폴리시클릭 아자인돌 화합물, 이들을 제조하는 방법 및이들을 함유하는 약제 조성물
JP2006504632A (ja) チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤
Hénon et al. Synthesis and biological evaluation of new dipyrrolo [3, 4-a: 3, 4-c] carbazole-1, 3, 4, 6-tetraones, substituted with various saturated and unsaturated side chains via palladium catalyzed cross-coupling reactions
US5808060A (en) Fused isoindolones
CN101528230A (zh) 作为钙通道阻断剂的吲哚并喹啉类化合物
JP4070810B2 (ja) タンパク質キナーゼｃの阻害剤としての縮合イソインドロン
KR930001407B1 (ko) 신규한 이소인돌 유도체 및 그의 염, 이의 제조방법 및 이를 포함하는 종양치료제
JPH09208466A (ja) 縮合多環式ヘテロ環誘導体

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115911

Country of ref document: FI

MA Patent expired